宏源药业
(301246)
| 流通市值：24.28亿 | | | 总市值：65.20亿 |
| 流通股本：1.49亿 | | | 总股本：4.00亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 585,181,497.3 | 421,862,807.47 | 863,628,565.73 | 311,204,485.99 |
| 应收票据及应收账款 | 417,449,398.5 | 381,954,346.87 | 383,024,961.17 | 427,320,818.85 |
| 其中：应收票据 | 211,535,341.86 | 171,380,626 | 164,158,954 | 225,016,957.6 |
| 应收账款 | 205,914,056.64 | 210,573,720.87 | 218,866,007.17 | 202,303,861.25 |
| 应收款项融资 | 262,353,682.83 | 220,681,896.81 | 135,647,320.64 | 246,315,485.63 |
| 预付款项 | 31,007,323.48 | 34,400,731.27 | 38,246,519.19 | 21,662,442.9 |
| 其他应收款合计 | 82,706,224.12 | 141,667,251.87 | 184,765,156.02 | 185,188,451.75 |
| 应收股利 | - | 61,500,000 | 102,500,000 | 102,500,000 |
| 存货 | 225,119,605.09 | 191,506,412.04 | 228,902,285.93 | 291,246,083.57 |
| 其他流动资产 | 40,088,322.35 | 344,331,949.83 | 311,792,071.8 | 59,107,290.97 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 3,080,763,286.56 | 3,202,265,631.78 | 3,299,108,622.93 | 3,549,201,051.53 |
| 非流动资产: | | | | |
| 长期股权投资 | 221,378,828.22 | 228,080,576.15 | 223,302,833.99 | 226,542,399.07 |
| 投资性房地产 | 3,999,734.57 | 4,020,712.2 | 4,041,689.83 | 4,062,667.46 |
| 固定资产 | 1,488,816,990.49 | 1,526,783,440.9 | 1,525,367,484.04 | 1,557,594,015.24 |
| 在建工程 | 476,410,446.83 | 375,858,582.74 | 92,907,640.98 | 44,434,188.08 |
| 使用权资产 | 7,143,492.43 | 7,323,366.48 | 7,683,114.56 | 7,683,114.56 |
| 无形资产 | 182,243,948.67 | 183,058,812.4 | 170,084,179.61 | 171,366,907.19 |
| 长期待摊费用 | 5,333,743.03 | 5,946,858.9 | 3,488,939.06 | 4,612,027.49 |
| 递延所得税资产 | 16,072,028.91 | 17,557,501.07 | 14,557,966.46 | 14,653,097.65 |
| 其他非流动资产 | 158,100,727.3 | 99,875,308.72 | 219,701,735.6 | 129,642,272.73 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 2,559,499,940.45 | 2,448,505,159.56 | 2,261,135,584.13 | 2,160,590,689.47 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 5,640,263,227.01 | 5,650,770,791.34 | 5,560,244,207.06 | 5,709,791,741 |
| 流动负债: | | | | |
| 短期借款 | - | - | 1,495,267.86 | - |
| 应付票据及应付账款 | 629,016,628.84 | 636,790,016.18 | 516,957,343.26 | 642,043,172.81 |
| 其中：应付票据 | 388,199,235.62 | 303,138,883.55 | 235,782,877.91 | 282,074,461.93 |
| 应付账款 | 240,817,393.22 | 333,651,132.63 | 281,174,465.35 | 359,968,710.88 |
| 合同负债 | 14,871,513.76 | 19,803,443.17 | 17,812,739.36 | 18,768,044.71 |
| 应付职工薪酬 | 13,262,114.63 | 31,026,001.9 | 12,467,685.5 | 12,441,361.11 |
| 应交税费 | 3,941,409.12 | 4,393,549.26 | 8,268,555.1 | 9,103,749.43 |
| 其他应付款合计 | 41,232,739.3 | 32,281,396.01 | 42,172,018.62 | 44,448,143.7 |
| 一年内到期的非流动负债 | 65,554,000 | 66,499,255.57 | 65,921,446 | 66,500,952.29 |
| 其他流动负债 | 107,992,372.1 | 124,034,583.55 | 121,043,385.03 | 171,276,545.96 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 875,870,777.75 | 914,828,245.64 | 786,138,440.73 | 964,581,970.01 |
| 非流动负债: | | | | |
| 长期借款 | 273,338,000 | 276,115,000 | 306,115,000 | 308,892,000 |
| 租赁负债 | 7,589,262.51 | 6,900,499.09 | 8,945,031.44 | 8,365,525.15 |
| 递延收益 | 69,230,692.77 | 71,552,258.08 | 69,264,939.81 | 71,575,798 |
| 递延所得税负债 | 21,724,174.61 | 21,537,352.98 | 20,012,567.67 | 20,012,567.67 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 371,882,129.89 | 376,105,110.15 | 404,337,538.92 | 408,845,890.82 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 1,247,752,907.64 | 1,290,933,355.79 | 1,190,475,979.65 | 1,373,427,860.83 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 400,006,800 | 400,006,800 | 400,006,800 | 400,006,800 |
| 资本公积 | 2,171,773,705.55 | 2,171,725,787.1 | 2,172,101,540.99 | 2,171,644,810.33 |
| 专项储备 | 3,312,944.76 | 1,887,041.01 | 2,416,232.5 | 745,355.26 |
| 盈余公积 | 185,239,736.88 | 185,239,736.88 | 176,374,800 | 176,374,800 |
| 未分配利润 | 1,632,177,132.18 | 1,600,978,070.56 | 1,618,868,853.92 | 1,587,592,114.58 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 4,392,510,319.37 | 4,359,837,435.55 | 4,369,768,227.41 | 4,336,363,880.17 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 4,392,510,319.37 | 4,359,837,435.55 | 4,369,768,227.41 | 4,336,363,880.17 |
| 负债和股东权益合计 | 5,640,263,227.01 | 5,650,770,791.34 | 5,560,244,207.06 | 5,709,791,741 |
| 公告日期 | 2024-04-23 | 2024-04-23 | 2023-10-28 | 2023-08-31 |
| 审计意见(境内) | | 标准无保留意见 | | |